Found this in an article today.
The hype surrounding mRNA vaccines has been lucrative for Moderna’s executives. This year, as share prices have soared on the whole and gyrated wildly on day-to-day vaccine news, Moderna insiders have sold more than $250 million worth of stock, according to executive compensation data company Equilar Inc. Bancel has sold more than $18 million since the Covid-19 vaccine program was announced, and investment companies he controls have sold $11 million more. Moderna says sales by executives are triggered by preexisting share-sales plans, and Bancel says the vast majority of his fortune is still tied up in Moderna stock.
Some scientists were particularly annoyed about a press release on May 18 from Moderna announcing “positive interim clinical data.” Its vaccine had produced neutralizing antibodies in the first eight volunteers, but the company didn’t indicate what kind of numbers those antibodies were being produced in, making it hard to judge how promising the results actually were. Moderna’s shares went up 20% anyway, and the company raised $1.3 billion in a secondary stock offering later that day.
The hype surrounding mRNA vaccines has been lucrative for Moderna’s executives. This year, as share prices have soared on the whole and gyrated wildly on day-to-day vaccine news, Moderna insiders have sold more than $250 million worth of stock, according to executive compensation data company Equilar Inc. Bancel has sold more than $18 million since the Covid-19 vaccine program was announced, and investment companies he controls have sold $11 million more. Moderna says sales by executives are triggered by preexisting share-sales plans, and Bancel says the vast majority of his fortune is still tied up in Moderna stock.
Some scientists were particularly annoyed about a press release on May 18 from Moderna announcing “positive interim clinical data.” Its vaccine had produced neutralizing antibodies in the first eight volunteers, but the company didn’t indicate what kind of numbers those antibodies were being produced in, making it hard to judge how promising the results actually were. Moderna’s shares went up 20% anyway, and the company raised $1.3 billion in a secondary stock offering later that day.